Charles E Barr
Overview
Explore the profile of Charles E Barr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dang L, Gruber S, Lee H, Dahabreh I, Stuart E, Williamson B, et al.
J Clin Transl Sci
. 2023 Oct;
7(1):e212.
PMID: 37900353
Increasing emphasis on the use of real-world evidence (RWE) to support clinical policy and regulatory decision-making has led to a proliferation of guidance, advice, and frameworks from regulatory agencies, academia,...
2.
Rizk J, Barr C, Rizk Y, Lewin J
Vaccine
. 2021 Aug;
39(41):6017-6018.
PMID: 34400020
No abstract available.
3.
Zhang J, Sridhar G, Barr C, Eichelberger B, Lockhart C, Marshall J, et al.
J Manag Care Spec Pharm
. 2020 Apr;
26(4):417-490.
PMID: 32223608
Background: There is a need for postmarketing evidence generation for novel biologics and biosimilars. Objective: To assess the feasibility, strengths, and limitations of the Biologics and Biosimilars Collective Intelligence Consortium...
4.
He M, Santiago Ortiz A, Marshall J, Mendelsohn A, Curtis J, Barr C, et al.
Pharmacoepidemiol Drug Saf
. 2019 Dec;
29(7):770-777.
PMID: 31854053
Purpose: The Centers for Medicare and Medicaid Services (CMS) mandated the transition from ICD-9 to ICD-10 codes on October 1, 2015. Postmarketing surveillance of newly marketed drugs, including novel biologics...
5.
Zhang J, Haynes K, Mendelsohn A, Marshall J, Barr C, McDermott C, et al.
Pharmacoepidemiol Drug Saf
. 2019 Dec;
29(7):778-785.
PMID: 31802568
Purpose: To assess the capture of biologics (originator and biosimilar) in the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Distributed Research Network (DRN), with a focus on medical claim National...
6.
Desai R, Kim S, Curtis J, Bosco J, Eichelberger B, Barr C, et al.
Pharmacoepidemiol Drug Saf
. 2019 Jul;
29(7):757-769.
PMID: 31298463
Purpose: As more biosimilars become available in the United States, postapproval noninterventional studies describing biosimilar switching and comparing effectiveness and/or safety between switchers and nonswitchers will play a key role...
7.
Travers K, Sallum R, Burns M, Barr C, Beattie M, Pashos C, et al.
Pharmacoepidemiol Drug Saf
. 2014 Aug;
24(4):389-98.
PMID: 25079108
Purpose: Patient registries are used to monitor safety, examine real-world effectiveness, and may potentially contribute to comparative effectiveness research. To our knowledge, life sciences industry (LSI)-sponsored registries have not been...
8.
Kabbinavar F, Flynn P, Kozloff M, Ashby M, Sing A, Barr C, et al.
Eur J Cancer
. 2012 Mar;
48(8):1126-32.
PMID: 22424880
Background: Bevacizumab prolongs overall and progression-free survival when added to fluorouracil-based chemotherapy in patients with metastatic colorectal cancer in randomised controlled trials (RCTs). However, gastrointestinal perforation (GIP) occurs in 1-2%...
9.
Hochberg M, Silverman S, Barr C, Miller P
J Clin Densitom
. 2010 Mar;
13(2):181-9.
PMID: 20347369
Bone turnover markers may provide a more rapid indication of patient response to osteoporosis treatment than bone mineral density (BMD) measurements. This post hoc analysis of data from the MOBILE...
10.
Cobden D, Niessen L, Barr C, Rutten F, Redekop W
Value Health
. 2009 Aug;
13(1):138-47.
PMID: 19695005
Objectives: Type 2 diabetes (T2D) treatment involves complex interactions between biological, psychological, and behavioral factors of care, requiring multifaceted efforts in clinical practice and disease management to reduce health and...